Table 4.
Selected novel agents in development in pancreatic adenocarcinoma in the metastatic setting
| NCT | Trial Design | N | Target | Sponsor |
|---|---|---|---|---|
| 02428270 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer |
24 | FAK MEK |
University Health Network, Toronto |
| 01839487 | Gem + nab-P ± PEGPH20 Rand phase II |
132 | Hyaluronan | Halozyme |
| 01959139 | mFOLFIRINOX ± PEGPH20 Rand phase II |
172 | Hyaluronan | SWOG/ S1313 |
| 01621243 | Gem + nab-P ± Necuparanib Rand phase II |
148 | Anti-stromal Heparin mimetic |
Momenta |
| 01647828 | Gem + nab-P ± Tarextumab (Alpine) Rand phase II |
140 | Notch, stem cell | OncoMed |
| 01844817 | Gem + nab-P ± OGX-427 (Rainier) Rand phase II |
132 | HSP27 | OncoGenix |
| 02101021 | Gem + nab-P ± Momelotinib Phase IB - rand ph II |
336 | JAK 1/JAK2 | Gilead |
| 02289898 | Gem + nab-P ± Demcizumab (Yosemite) Rand phase II |
201 | Anti-DLL4, stem cell |
OncoMed |
| 02077881 | Gem + nab-P ± Indoximod Rand phase II |
80 | IDO | NewLink Genetics |
| 02109445 | Gem + nab-P ± PF-03084014 Rand phase II |
193 | γ-Secretase inhibitor, Notch |
Pfizer |
| 02194829 | Gem + nab-P ± MK-1775 Phase IB - rand ph II |
133 | Wee-1 inhibitor | Merck |
| 02050178 | Gem + nab-P + OMP-54F28 Phase IB |
20 | Frizzled | OncoMed |
| 02101580 | Gem + nab-P + ADIPEG 20 Phase IB |
21 | Arginine depletion |
Polaris |